PRCT
PROCEPT BioRobotics Corporation NASDAQ Listed Sep 15, 2021$20.90
-0.76%
vs $21.06
Mkt Cap $1.2B
52w Low $19.35
3.6% of range
52w High $62.17
50d MA $25.54
200d MA $29.93
P/E (TTM)
—
EV/EBITDA
—
P/B
3.2x
Debt/Equity
0.1x
ROE
-26.1%
P/FCF
-20.1x
RSI (14)
25.60
ATR (14)
$1.62
Beta
0.93
50d MA
$25.54
200d MA
$29.93
Avg Volume
1.6M
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
900 Island Drive · San Jose, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -0.55 | -0.56 | -1.8% | 21.71 | +10.9% | +10.7% | +2.5% | +0.8% | +1.4% | -1.5% | — |
| Feb 25, 2026 | AMC | -0.32 | -0.53 | -65.6% | 27.84 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% | — |
| Nov 4, 2025 | AMC | -0.41 | -0.38 | +7.3% | 35.02 | -6.5% | -9.7% | -1.0% | +2.0% | -3.1% | +1.3% | — |
| Aug 6, 2025 | AMC | -0.41 | -0.35 | +14.6% | 45.69 | -8.1% | -13.4% | -3.0% | +0.9% | -0.4% | +4.6% | — |
| Apr 24, 2025 | AMC | -0.49 | -0.45 | +8.2% | 52.56 | -1.1% | -0.1% | +3.2% | +4.0% | -4.1% | -2.1% | — |
| Feb 25, 2025 | AMC | -0.34 | -0.35 | -2.9% | 62.71 | +4.5% | +8.6% | -4.5% | -1.0% | -5.8% | +7.2% | — |
| Oct 28, 2024 | AMC | -0.48 | -0.40 | +16.7% | 91.00 | -3.3% | +6.3% | -3.8% | -3.3% | +2.5% | +5.2% | — |
| Aug 1, 2024 | AMC | -0.52 | -0.50 | +3.8% | 62.00 | -4.9% | -7.5% | -1.9% | +7.6% | -0.8% | +3.0% | — |
| May 1, 2024 | AMC | -0.55 | -0.51 | +7.3% | 60.61 | +3.3% | +1.9% | +4.2% | -4.5% | +2.2% | -3.9% | — |
| Feb 27, 2024 | AMC | -0.44 | -0.54 | -22.7% | 50.75 | -5.4% | -2.7% | -2.1% | +1.5% | -2.4% | -3.1% | — |
| Nov 1, 2023 | AMC | -0.53 | -0.51 | +3.8% | 27.55 | +8.0% | +18.4% | +4.0% | -3.2% | +0.8% | -0.7% | — |
| Jul 27, 2023 | AMC | -0.57 | -0.56 | +1.8% | 35.13 | +1.6% | +0.4% | -2.4% | -1.5% | +6.1% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 11 | Leerink Partners | Downgrade | Outperform → Market Perform | $29 | $29.09 | $28.17 | -3.2% | -4.8% | -7.2% | -9.7% | -4.8% | -5.4% |
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.71 | $24.08 | +10.9% | +10.7% | +2.5% | +0.8% | +1.4% | -1.5% |
| Mar 2 | Truist | Maintains | Buy → Buy | — | $22.69 | $22.16 | -2.3% | +14.1% | +1.4% | +1.1% | -4.6% | -4.5% |
| Feb 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Feb 26 | Oppenheimer | Downgrade | Outperform → Perform | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Feb 26 | BofA Securities | Downgrade | Neutral → Underperform | — | $27.84 | $19.61 | -29.6% | -15.1% | -4.0% | +14.1% | +1.4% | +1.1% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $33.78 | $34.30 | +1.5% | -3.1% | -2.0% | +6.9% | -4.5% | +0.5% |
| Dec 8 | BofA Securities | Downgrade | Buy → Neutral | — | $35.86 | $33.62 | -6.2% | -5.1% | +2.9% | +2.0% | +0.9% | -0.1% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.41 | $30.38 | -0.1% | -2.9% | +12.4% | +6.8% | +1.2% | -5.1% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $35.02 | $32.73 | -6.5% | -9.7% | -1.0% | +2.0% | -3.1% | +1.3% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $35.02 | $32.73 | -6.5% | -9.7% | -1.0% | +2.0% | -3.1% | +1.3% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $35.02 | $32.73 | -6.5% | -9.7% | -1.0% | +2.0% | -3.1% | +1.3% |
| Oct 15 | Truist | Maintains | Buy → Buy | — | $33.92 | $33.85 | -0.2% | -0.5% | +0.5% | -2.9% | +5.3% | -0.3% |
| Sep 16 | BTIG | Maintains | Neutral → Neutral | — | $38.00 | $37.89 | -0.3% | +4.1% | -5.8% | +2.0% | -1.7% | +2.9% |
| Sep 2 | Oppenheimer | Upgrade | Perform → Outperform | — | $40.17 | $41.89 | +4.3% | -1.5% | -4.4% | +1.3% | +6.1% | -4.3% |
| Aug 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $45.69 | $42.00 | -8.1% | -13.4% | -3.0% | +0.9% | -0.4% | +4.6% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $45.69 | $42.00 | -8.1% | -13.4% | -3.0% | +0.9% | -0.4% | +4.6% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $58.17 | $58.35 | +0.3% | -0.3% | -1.7% | +3.3% | -1.0% | -2.2% |
| Apr 25 | BofA Securities | Maintains | Buy → Buy | — | $52.56 | $51.96 | -1.1% | -0.1% | +3.2% | +4.0% | -4.1% | -2.1% |
| Apr 11 | Truist | Maintains | Buy → Buy | — | $50.73 | $50.60 | -0.3% | +2.6% | +3.2% | -1.6% | -0.2% | +0.4% |
| Feb 26 | Morgan Stanley | Maintains | Overweight → Overweight | — | $62.71 | $65.56 | +4.5% | +8.6% | -4.5% | -1.0% | -5.8% | +7.2% |
| Feb 26 | Truist | Maintains | Buy → Buy | — | $62.71 | $65.56 | +4.5% | +8.6% | -4.5% | -1.0% | -5.8% | +7.2% |
| Oct 30 | Truist | Maintains | Buy → Buy | — | $96.69 | $97.00 | +0.3% | -3.8% | -3.3% | +2.5% | +5.2% | -1.7% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $69.62 | $73.50 | +5.6% | +6.3% | +0.2% | -2.5% | -0.8% | +1.8% |
| Sep 16 | TD Cowen | Maintains | Buy → Buy | — | $81.11 | $82.86 | +2.2% | +1.1% | -2.7% | +4.0% | -0.2% | +2.7% |
| Sep 3 | Truist | Maintains | Buy → Buy | — | $79.00 | $78.14 | -1.1% | -5.0% | +1.3% | +0.4% | +0.3% | +0.1% |
| Aug 22 | BofA Securities | Maintains | Buy → Buy | — | $83.44 | $85.50 | +2.5% | -3.8% | -1.2% | -1.7% | +4.4% | -1.8% |
| Aug 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.00 | $58.95 | -4.9% | -7.5% | -1.9% | +7.6% | -0.8% | +3.0% |
| Aug 2 | Truist | Maintains | Buy → Buy | — | $62.00 | $58.95 | -4.9% | -7.5% | -1.9% | +7.6% | -0.8% | +3.0% |
| Jul 16 | Truist | Maintains | Buy → Buy | — | $66.84 | $67.85 | +1.5% | +4.4% | +2.1% | -6.3% | +1.1% | +2.4% |
| May 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $64.31 | $65.00 | +1.1% | -4.5% | +2.2% | -3.9% | +4.4% | -0.6% |
| May 6 | TD Cowen | Maintains | Buy → Buy | — | $64.31 | $65.00 | +1.1% | -4.5% | +2.2% | -3.9% | +4.4% | -0.6% |
| May 2 | Truist | Maintains | Buy → Buy | — | $60.61 | $62.63 | +3.3% | +1.9% | +4.2% | -4.5% | +2.2% | -3.9% |
| Feb 28 | Truist | Maintains | Buy → Buy | — | $50.75 | $48.00 | -5.4% | -2.7% | -2.1% | +1.5% | -2.4% | -3.1% |
| Jan 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $42.21 | $42.98 | +1.8% | +15.1% | -2.1% | -1.0% | -0.6% | +0.7% |
| Dec 22 | Truist | Maintains | Buy → Buy | — | $42.55 | $43.07 | +1.2% | -1.1% | +1.5% | +0.7% | -0.1% | -2.4% |
| Dec 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $39.36 | $39.79 | +1.1% | +3.0% | +3.6% | +3.4% | -2.6% | -0.6% |
| Sep 13 | Truist | Maintains | Buy → Buy | — | $33.98 | $33.97 | -0.0% | -0.7% | -1.7% | -1.1% | +0.7% | +0.4% |
| May 31 | William Blair | Maintains | Outperform → Outperform | — | $31.40 | $31.82 | +1.3% | +6.5% | -2.9% | +0.0% | -3.0% | +6.4% |
| May 1 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $30.39 | $29.49 | -3.0% | +3.0% | -8.8% | +2.0% | -1.0% | -1.0% |
| May 1 | Truist | Maintains | Buy → Buy | — | $30.39 | $29.49 | -3.0% | +3.0% | -8.8% | +2.0% | -1.0% | -1.0% |
| Apr 28 | Truist | Maintains | Buy → Buy | — | $26.70 | $26.78 | +0.3% | +13.8% | +3.0% | -8.8% | +2.0% | -1.0% |
| Apr 28 | BofA Securities | Maintains | Buy → Buy | — | $26.70 | $26.78 | +0.3% | +13.8% | +3.0% | -8.8% | +2.0% | -1.0% |
| Jan 31 | Truist | Maintains | Buy → Buy | — | $37.55 | $37.75 | +0.5% | +3.6% | +0.6% | +1.3% | -1.4% | -5.8% |
| Jan 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $32.49 | $32.38 | -0.3% | +4.3% | +7.6% | +7.2% | +0.7% | -2.1% |
| Dec 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $42.81 | $43.06 | +0.6% | +0.5% | +3.4% | -5.2% | +0.1% | +1.8% |
| Nov 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $44.00 | $39.24 | -10.8% | -9.4% | -1.5% | +3.1% | -2.7% | +13.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Templin Barry LOff | EVP, Chief Technology Officer | Sell | 358 | $28.48 | $10K | 68,953 | -4.81% | -5.38% |
| Jun 8, 2026 | Waters KevinOff | EVP, CFO | Sell | 357 | $28.48 | $10K | 151,201 | -4.81% | -5.38% |
| Jun 8, 2026 | Nouri AlalehOff | EVP, CLO, CORP. SEC. | Sell | 285 | $28.48 | $8K | 105,069 | -4.81% | -5.38% |
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
Jun 10
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
PROCEPT BioRobotics reported Q1 2026 results, emphasizing operational restructuring toward accountability and commercial discipline in its surgical robotics urology focus.
Apr 29
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
Puckett's appointment to a senior finance or operations role at PROCEPT BioRobotics brings extensive experience from Forest Laboratories and Affymetrix, potentially strengthening the company's operational and financial management capabilities.
Mar 6
8-K · 7.01
! Medium
PROCEPT BioRobotics Corporation -- 8-K 7.01: Regulation FD Disclosure
PROCEPT BioRobotics disclosed its Investor Day presentation, providing investors access to updated company guidance and strategic messaging through live and archived recordings on its investor relations website.
Feb 26
8-K
PROCEPT BioRobotics Corporation -- 8-K Filing
PROCEPT BioRobotics reported record Q4 2025 procedure volume of 12,200 and sold 65 new robotic systems, demonstrating strong surgical adoption momentum in its urology-focused business.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bnp Paribas Asset Management Holding S.a. | 3,089,378 | $77M | — | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 2,421,362 | $61M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,399,067 | $60M | New | Mar 2026 |
| 4 | Morgan Stanley | 1,686,982 | $53M | — | Dec 2025 |
| 5 | Fmr Llc | 1,461,904 | $37M | Reduced | Mar 2026 |
| 6 | Artisan Partners Limited Partnership | 1,187,349 | $30M | Reduced | Mar 2026 |
| 7 | Champlain Investment Partners, Llc | 1,136,322 | $28M | Reduced | Mar 2026 |
| 8 | Point72 Asset Management | 1,128,543 | $28M | New | Mar 2026 |
| 9 | Millennium Management | 1,005,458 | $25M | Added | Mar 2026 |
| 10 | Divisadero Street Capital Management, Lp | 866,338 | $22M | New | Mar 2026 |
| 11 | Mirova | 723,842 | $18M | New | Mar 2026 |
| 12 | Marshall Wace, Llp | 698,232 | $17M | Added | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 630,689 | $16M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 552,018 | $14M | — | Mar 2026 |
| 15 | Ubs Group Ag | 504,493 | $13M | Reduced | Mar 2026 |
| 16 | Bellevue Group Ag | 502,286 | $13M | Reduced | Mar 2026 |
| 17 | Rhenman & Partners Asset Management Ab | 475,000 | $12M | Reduced | Mar 2026 |
| 18 | William Blair Investment Management, Llc | 424,309 | $11M | Added | Mar 2026 |
| 19 | Janus Henderson Group Plc | 384,246 | $10M | New | Mar 2026 |
| 20 | Johnson & Johnson | 357,939 | $9M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.19B
Enterprise Value
$938.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
10.70x
P/B
3.18x
P/S
3.62x
P/FCF
-20.12x
EV/EBITDA
—
Shares Out
55.7M
Financials (TTM)
Revenue
$322.0M
Net Income
-$102.5M
EBITDA
-$92.1M
Free Cash Flow
-$58.3M
Op Cash Flow
-$49.0M
EPS Basic
$-1.72
EPS Diluted
$-1.82
EPS Forward
$-1.54
Gross Margin
63.0%
Op Margin
-33.9%
Net Margin
-31.8%
Balance Sheet
Total Assets
$508.1M
Total Liab.
$142.2M
Total Equity
$365.9M
Cash
$286.5M
LT Debt
$51.6M
Book Value/Sh
$6.57
Debt/Equity
0.14x
Current Ratio
6.85
Quick Ratio
5.77
Returns & Growth
ROE
-26.1%
ROA
-18.8%
ROIC
-23.5%
Rev Growth YoY
+37.2%
EPS Growth YoY
+1.7%
Price Returns
2W
-0.2%
1M
+9.5%
3M
+16.0%
6M
-16.9%
12M
-54.6%
Technicals
52W High
$62.17
52W Low
$19.35
50d MA
$25.54
200d MA
$29.93
RSI (14)
25.60
ATR (14)
$1.62
Beta
0.93
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$44.50
High
$62.00
Low
$30.00
Median
$43.00
Data updated apr 26, 2026 8:35pm
· Source: financialmodelingprep.com